Exelixis reported $408M in Gross Profit on Sales for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Acadia Pharmaceuticals ACAD:US USD 134.08M 5.5M
Agios Pharmaceuticals AGIO:US USD 3.9M 898K
Akebia Therapeutics AKBA:US USD 66.43M 47.15M
Amgen AMGN:US USD 5.09B 28M
AstraZeneca AZN:LN USD 8.7B 168M
Bayer BAYN:GR EUR 7.23B 198M
Biomarin Pharmaceutical BMRN:US USD 410.25M 21.19M
Bluebird Bio BLUE:US USD 71K 297K
Bristol Myers Squibb BMY:US USD 8.89B 21M
Eisai 4523:JP JPY 140.84B 11.6B
Eli Lilly And LLY:US USD 5.75B 391.2M
Esperion Therapeutics ESPR:US USD 14.66M 2.18M
Exelixis EXEL:US USD 408M 11.56M
Glaxosmithkline GSK:US GBP 5.2B 244M
Merk MRK:US USD 10.47B 610M
Moderna Inc MRNA:US USD 3.17B 902M
Nektar Therapeutics NKTR:US USD 15.79M 2.86M
Neurocrine Biosciences NBIX:US USD 404.3M 22.5M
Novartis NOVN:VX USD 9.16B 21M
Pfizer PFE:US USD 14.47B 2.08B
Puma Biotechnology PBYI:US USD 48.84M 4.23M
Seattle Genetics SGEN:US USD 419.94M 17.76M
Takeda 4502:JP JPY 760.58B 63.72B
Ultragenyx Pharmaceutical RARE:US USD 98.03M 15.96M
YTE INCY:US USD 872.94M 98.92M